Tempest Therapeutics Stock

tempesttx.comHealthcareFounded: 1900Funding to Date: $75.2MM

Tempest Therapeutics is a clinical-stage biotechnology company advancing small molecule therapeutics that modulate anti-tumor immunity pathways.

Register for Details

For more details on financing and valuation for Tempest Therapeutics, register or login.

Please provide your first name.
Please provide your last name.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Click here to log in

Enterprise Value (based on primary financings)

Enterprise Value

View Enterprise Value for Tempest Therapeutics.

Register Today

Team

Management Team

Chan Whiting Ph.D
Senior Vice President of Research & Development
Thomas Dubensky Ph.D
Chief Executive Officer, President & Board Member
Peppi Prasit Ph.D
Acting Chief Scientific Officer & Director
Ginna Laport MD
Chief Medical Officer

Board Members

Bradley Bolzon Ph.D
Versant Venture Management
Thomas Woiwode Ph.D
Versant Venture Management
Robert Weisskoff Ph.D
F-Prime Capital Partners
Stella Xu Ph.D
Quan Capital
Peppi Prasit Ph.D
Thomas Dubensky Ph.D
Tempest Therapeutics

Other companies like Tempest Therapeutics in the Healthcare sector

Sector
Last Round Est. Valuation
$2.15B
Sector
Last Round Est. Valuation
$3.67B
Sector
Last Round Est. Valuation
$334.19MM
Sector
Last Round Est. Valuation
$317.32MM
Sector
Last Round Est. Valuation
$1.08B
Sector
Last Round Est. Valuation
$4.26B
Sector
 
 
Sector
Last Round Est. Valuation
$885.01MM